The FDA on August 16, 2018 approved LENVIMA® capsules for the first-line treatment of patients with unresectable HepatoCellular Carcinoma (HCC). LENVIMA® is a product of Eisai Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement